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Tick-borne encephalitis virus (TBEV) is a leading cause of human neuroinfections in Europe and Northeast Asia. There are no
antiviral therapies for treating TBEV infection. A series of nucleoside analogues was tested for the ability to inhibit the replica-
tion of TBEV in porcine kidney cells and human neuroblastoma cells. The interactions of three nucleoside analogues with viral
polymerase were simulated using advanced computational methods. The nucleoside analogues 7-deaza-2=-C-methyladenosine
(7-deaza-2=-CMA), 2=-C-methyladenosine (2=-CMA), and 2=-C-methylcytidine (2=-CMC) inhibited TBEV replication. These
compounds showed dose-dependent inhibition of TBEV-induced cytopathic effects, TBEV replication (50% effective concentra-
tions [EC50]of 5.1 0.4M for 7-deaza-2=-CMA, 7.1 1.2M for 2=-CMA, and 14.2 1.9M for 2=-CMC) and viral antigen
production. Notably, 2=-CMCwas relatively cytotoxic to porcine kidney cells (50% cytotoxic concentration [CC50] of50M).
The anti-TBEV effect of 2=-CMA in cell culture diminished gradually after day 3 posttreatment. 7-Deaza-2=-CMA showed no de-
tectable cellular toxicity (CC50> 50M), and the antiviral effect in culture was stable for>6 days posttreatment. Computa-
tional molecular analyses revealed that compared to the other two compounds, 7-deaza-2=-CMA formed a large cluster near the
active site of the TBEV polymerase. High antiviral activity and low cytotoxicity suggest that 7-deaza-2=-CMA is a promising can-
didate for further investigation as a potential therapeutic agent in treating TBEV infection.
Tick-borne encephalitis virus (TBEV) belongs to the Flaviviri-dae family, which includes other human- and animal-patho-
genic viruses of global importance, such as West Nile virus
(WNV), dengue virus (DENV), Japanese encephalitis virus (JEV),
yellow fever virus (YFV), and hepatitis C virus (HCV) (1). TBEV
virions are approximately 50 nm in diameter and are composed of
a spherical nucleocapsid surrounded by a host-derived lipid bi-
layer. The TBEV genome is a single-stranded, plus-sense RNA
about 11 kb in length that encodes a single polyprotein; this poly-
protein is co- and posttranslationally processed into 3 structural
and 7 nonstructural proteins (2).
In Europe and Northeast Asia, tick-borne encephalitis (TBE)
represents one of the most important and serious neuroviral in-
fections. More than 13,000 clinical cases of TBE, including nu-
merous deaths, are reported annually worldwide (3, 4). The con-
siderable increase in TBE incidence in countries where it is
endemic and the emergence of the disease in several Western and
Northern European countries have made TBE an increasing pub-
lic health risk. In Europe, the most affected areas are southern
Germany, Switzerland, Austria, the Czech Republic, Slovakia,
Hungary, Slovenia, the Baltic states, Poland, parts of Scandinavia,
and European Russia (5). The disease is usually biphasic: the first
stage is febrile with flu-like symptoms, while the second phase
manifests most often as meningitis, encephalitis, meningoenceph-
alitis, meningoencephalomyelitis, and radiculitis. There are long-
lasting or permanent neuropsychiatric sequelae in 10 to 20% of
the infected patients (6). Although human vaccines against TBEV
are currently available, the vaccination coverage remains quite low
in several of the countries where TBEV is endemic (7). No specific
antiviral therapy has been developed for TBE, and patient treat-
ment is limited to supportive care (8). There is thus an urgent need
for an effective approach to treatment that is based on specific
inhibitors of TBEV replication.
Chemically modified nucleosides, also called nucleoside ana-
logues or nucleoside inhibitors, represent the largest class of anti-
viral drugs. These compounds generally act via DNA or RNA
chain termination with the potential exception of ribavirin, for
which the mechanism may depend upon the virus and experimen-
tal system (9). Nucleoside analogues have been widely used as
inhibitors of numerous medically important viruses, including
HIV, herpesvirus, and hepatitis B virus (10, 11). Regarding flavi-
viruses, nucleoside analogues have been demonstrated to be effi-
cacious in HCV replicon assays (12–16) and also against DENV
(17–21), WNV (22), and YFV (23). Some of them were described
as broad-spectrum inhibitors of various RNA viruses (24–27). 2=-
Modified nucleoside analogues exhibit a high antiflavivirus activ-
ity and good pharmacokinetic properties (9). For TBEV inhibi-
tion, however, these compounds have not been tested thoroughly,
if they have been tested at all. The high degree of homology be-
tween the polymerases of TBEV and other flaviviruses (28) sug-
gests, however, that an investigation of nucleoside analogues as
inhibitors of TBEV would be worthwhile.
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In the present study, a series of nucleoside analogues were
tested for the ability to inhibit TBEV replication in cell culture.
Particular attention was paid to chemically modified nucleosides
that have reported antiviral activity against other flaviviruses, es-
pecially HCV (14) or hemorrhagic fever-associated flaviviruses
(i.e., Alkhurma hemorrhagic fever virus, Omsk hemorrhagic fever
virus, and Kyasanur Forest disease virus) (29). Compounds with
favorable inhibitory profiles in the virus titer reduction assays
were further assayed for the ability to inhibit virus-induced cyto-
pathic effects and to suppress viral antigen expression in infected
cell cultures. The lead compounds were subsequently evaluated
for dose-response inhibition of TBEV replication and for poten-
tial cytotoxic effects on host cells. Based on these screens, we
identified three compounds with strong anti-TBEV activity. The
favorable characteristics of one of these compounds, 7-deaza-2=-
C-methyladenosine (7-deaza-2=-CMA), indicate that it merits
further investigation as a therapeutic agent for treating TBEV in-
fections.
MATERIALS AND METHODS
Cell cultures, virus strains, and antiviral compounds. Porcine kidney
stable (PS) cells were cultured at 37°C in Leibovitz (L-15) medium sup-
plemented with 3% precolostral calf serum and a 1% mixture of penicillin
and glutamine (Sigma-Aldrich, Prague, Czech Republic) (30). Human
neuroblastoma UKF-NB-4 cells were cultured at 37°C in 5% CO2 in Is-
cove’s modified Dulbecco’s medium (IMDM) supplemented with 10%
fetal bovine serum and a 1% mixture of penicillin and streptomycin (Sig-
ma-Aldrich) (31). All experiments were performed with TBEV strains
Hypr and Neudoerfl, which are representatives of the West European
TBEV subtype. Ribavirin and 2=-C-methyladenosine (2=-CMA) were syn-
thesized at the Institute of Organic Chemistry and Biochemistry (Prague,
Czech Republic). 7-deaza-2=-C-methyladenosine (7-deaza-2=-CMA), 2=-
C-methylcytidine (2=-CMC), and 6-azauridine were purchased from Car-
bosynth (Compton, United Kingdom). Mericitabine was purchased from
ChemScene (Monmouth Junction, NJ). The test compounds were solu-
bilized in 100% (vol/vol) dimethyl sulfoxide (DMSO) to yield 10 mM
stock solutions.
Viral titer reduction assay. PS or UKF-NB-4 cells were seeded in
96-well plates (approximately 2 104 cells per well) and incubated for 24
h to form a confluent monolayer. Following incubation, the medium was
aspirated from the wells and replaced with 200 l of fresh medium con-
taining a 50 M concentration of the test compound (three wells per
compound). The cells were immediately infected with the Hypr or Neu-
doerfl TBEV strain at a multiplicity of infection (MOI) of 0.1. As a nega-
tive control, DMSO was added to virus- and mock-infected cells at a final
concentration of 0.5% (vol/vol). After 72 h of incubation, the medium
was collected and immediately frozen at 80°C. Viral titers were deter-
mined by plaque assay.
Plaque assay. Virus titers were assayed using PS cell monolayers as
described previously (32). Briefly, 10-fold dilutions of TBEV were pre-
pared in 24-well tissue culture plates, and PS cells were added in suspen-
sion (0.6  105 to 1.5  105 cells per well). After a 4-h incubation, the
suspension was overlaid with 1.5% (wt/vol) carboxymethylcellulose in
L-15 medium. Following a 5-day incubation at 37°C, the infected plates
were washed with phosphate-buffered saline (PBS) and the cell monolay-
ers were stained with naphthalene black. The virus titer was expressed as
PFU per milliliter.
CPE inhibition assay and CPE quantification. The PS cells were
seeded in 96-well plates, the test compounds were added, and the cells
were infected with TBEV as described for the viral titer reduction assay.
Culture medium was collected 3 to 4 days postinfection (p.i.) to yield a 40
to 50% cytopathic effect (CPE) in virus control wells. The CPE was mon-
itored visually using an Olympus BX-5 microscope equipped with an
Olympus DP-70 charge-coupled-device (CCD) camera. To quantify the
CPE, both cell death and viability were determined using commercially
available colorimetric in vitro assays. Cell death was evaluated using the
CytoTox 96 nonradioactive cytotoxicity assay (Promega, WI) by follow-
ing the manufacturer’s instructions. This assay is based on quantitative
measurement of lactate dehydrogenase, a stable cytosolic enzyme that is
released upon cell lysis. Cell death was estimated as the percentage of
colorimetric absorbance at 490 nm by the compound-treated cells relative
to the absorbance by chemically lysed cells. Cell viability was evaluated by
determining formazan exclusion in confluent cell cultures in a colorimet-
ric assay utilizing Dojindo’s highly water-soluble tetrazolium salt (Cell
Counting Kit-8; Dojindo Molecular Technologies, MD). Cell viability was
expressed as the percentage of absorbance at 450 nm by compound-
treated cells relative to the absorbance by DMSO-treated cells.
Immunofluorescence staining. PS cells were cultured on slides
treated with the test compound (0 to 50M) and infected with the TBEV
Hypr strain at an MOI of 0.1. At day 4 postinfection, the cells were sub-
jected to cold acetone-methanol (1:1) fixation for 10 min, rinsed in saline,
and blocked with 10% fetal bovine serum. Cells were labeled with a mouse
monoclonal antibody that recognizes the flavivirus group surface antigen
(1:250; Sigma-Aldrich, Prague, Czech Republic) by incubation for 1 h at
37°C. After a washing with saline-Tween 20 (0.05% [vol/vol]), the cells
were labeled with an anti-mouse goat secondary antibody conjugated with
fluorescein isothiocyanate (FITC) (1:500) by incubation for 1 h at 37°C.
The cells were counterstained with 4=,6-diamidino-2-phenylindole
(DAPI) (1 g ml1; Sigma-Aldrich) for 30 min at 37°C and mounted in
2.5% 1,4-diazabicyclo[2.2.2]octane (DABCO; Sigma-Aldrich). The im-
ages were acquired with an Olympus IX71 epifluorescence microscope
equipped with a Hammamatsu OrcaR2 camera and controlled using Xcel-
lence software. The images were processed using Fiji software (33).
Cytotoxicity assays. PS cell monolayers in 96-well plates were treated
with test compounds at a concentration range of 0 to 50 M (2-fold
dilutions, three wells per concentration). At 4 days p.i., the potential cy-
totoxicity of test compounds was determined in terms of cell viability and
death using Cell Counting Kit-8 (Dojindo Molecular Technologies) and
the CytoTox 96 nonradioactive cytotoxicity assay (Promega, WI), respec-
tively, as described for CPE quantification. The concentration of com-
pound that reduced cell viability by 50% was considered the 50% cyto-
toxic concentration (CC50).
Dose-response studies with 2=-CMA, 7-deaza-2=-CMA, and 2=-
CMC.PS cell monolayers that were cultured for 24 h in 96-well plates were
treated with 200 l of medium containing the test compounds (2=-CMA,
7-deaza-2=-CMA, and 2=-CMC) at concentrations from 0 to 50 M (2-
fold dilution, three wells per concentration) and infected with the TBEV
Hypr strain at an MOI of 0.1. The medium was collected from the wells at
1-day intervals (postinfection days 1 to 6), and the viral titers were deter-
mined by plaque assays. The obtained virus titers were utilized to con-
struct TBEV growth curves and dose-response curves for selected nucle-
oside inhibitors. The dose-response curves on postinfection days 3 and 4
were used to estimate the most widely used measures of drug potency: the
50% effective concentration (EC50; the concentration of compound
required to inhibit the viral titer by 50% compared to the control
value), the selectivity index (SICC50/EC50), and the slope value (Hill
coefficient). The EC50s were calculated as follows: a dose-response
inhibition curve was fitted to a four parameter logistic curve using
Prism 5.04 software (GraphPad, Inc., CA) according to the equation
Y  Bottom  Top  Bottom ⁄ 1  10Hill coefficientlogEC50X . In this
equation, X is the logarithm of the concentration, Y is the logarithm of the
titer, bottom and top correspond to the asymptotes of the sigmoidal
curve, Hill coefficient corresponds to the slope at the inflection point of
the curve, and log EC50 is the calculated midpoint of the curve. The EC50
was calculated as 10logEC50. The standard errors of the EC50s were esti-
mated by the delta method.
Computer-aided protein modeling and preparation, and protein-
ligand exploration and clustering. The crystal structures of viral poly-
merases from HCV (PDB codes 1nb4 and 1nb6), WNV (PDB code 2hfz),
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and JEV (PDB code 4k6m) were used for computer simulations that
would complement the experimental results from this study. The TBEV
structure was modeled using Modeler (34). The models were evaluated
using the protein model-qualifying servers ModFOLD, QMEAN, and
RESPROX (35–37). Based on a consensus, the best-ranked TBEV model
was then selected for subsequent in silico experiments. Since X-ray crys-
tallography methods do not resolve hydrogen atoms, Schrödinger’s Mae-
stro Protein Preparation Wizard was used for each viral polymerase
structure to assign hydrogen atoms and to optimize the assigned hydro-
gen-bond network (38). The respective ligands for each protein structure
were removed prior to preparation. After protein preparation, an energy
minimization (using the default conditions in Schrödinger’s Maestro
package) (39) was performed for each crystal structure, including the
modeled TBEV polymerase structure, to alter the initial conformation
and to remove any steric clashes prior to simulations. In addition, the
HCV-UTP bound structure (PDB code 1nb6) has two Mn2 ions as co-
factors, with several water molecules surrounding the nucleoside. These
were also added to all structures and remained constrained for all subse-
quent simulations.
We used the Protein Energy Landscape Explorer (PELE) algorithm to
perform protein-ligand simulations of the three nucleoside triphosphate
analogues identified in this study and the aforementioned viral poly-
merases. For the simulations, we used the triphosphate form of the nucle-
oside analogues (2=-CMA-TP, 2=-CMC-TP, and 7-deaza-2=-CMA-TP)
since they are phosphorylated in vivo. A detailed explanation of the PELE
algorithm can be found in references (40 and 41), and its many uses can be
seen at https://pele.bsc.es/. Briefly, PELE performs three steps. First, local-
ized ligand perturbations and protein perturbations are performed using
an anisotropic network model (ANM) (42) to move the alpha-carbon
backbone toward a new position after minimization. Second, PELE opti-
mizes amino acid side chains in proximity of the ligand using steric filters
and a rotamer library (43). Finally, PELE uses a truncated Newton mini-
mizer and a surface generalized implicit solvent for minimization, achiev-
ing a local minimum after the initial perturbation (44). These steps are
repeated for a desired number of iterations and are performed in parallel
using several computer-processing units (CPUs). The output is a series of
trajectories that represent conformational changes of the side chains and
ligand exploration. A Monte Carlo Metropolis criterion is implemented in
the PELE algorithm that accepts or rejects these trajectories based on their
calculated energies: if they are equal to or less than (accepts) or greater
than (rejects) the initial calculated energy (45). To calculate the energy,
the PELE algorithm uses a standard force field that describes the potential
energy of a molecular system, known as optimized potentials for liquid
simulations (OPLS-2005) (46). The only parameters that were altered
from the unconstrained ligand migration ready-made script provided by
the PELE server were the ANM type, which was set to 4, and the addition
of ANM mode 6 for favorable protein perturbations. The number of iter-
ations was increased to 2,000 for increased sampling.
Cluster analysis was performed for the TBEV PELE simulations using
pyProCT (47), a Python cluster analysis tool specifically adapted for
biomolecules. Regular cluster analysis methods require a deep under-
standing of the data set and the algorithm. In addition, these methods are
sensitive to small changes in its parameters. Instead of forcing users to
perform a blind analysis, pyProCT implements a hypothesis-driven pro-
tocol. First, the user employs domain knowledge to characterize the de-
sired result in terms of measurable clustering attributes (e.g., maximum
and minimum number of clusters, size, noise, cluster separation, etc.)
Second, the software searches the clustering space to obtain the clusters
that best fit the hypothesis. The same script was used for each nucleoside
triphosphate analogue in the PELE protein-ligand exploration simula-
tions of the TBEV-modeled polymerase. The script instructs pyProCT to
calculate the distances of each nucleoside using (i) an iterative superposi-
tion of the protein backbone and (ii) the calculated distances between the
heavy atoms and the geometrical center of the ligand. The K-medoids,
DBSCAN, spectral clustering, hierarchical (single-linkage), and GROMOS
clustering algorithms were used, with up to 50 parameterizations for each
one. The allowed clusterings had to have 3 to 20 clusters with a minimum
of 300 elements. No more than 20% of the elements could be tagged as
noise. The evaluation function that chose the best clustering was a com-
bination of the silhouette index and a naive cohesion measure. This choice
of evaluation functions favors results in which the clusters are well sepa-
rated with a special emphasis on their compactness. Finally, the “atom-
ic_distances” postprocessing option was used in order to obtain a human-
readable file with the per-element distances between serine 331 (Ser331)
of the TBEV modeled polymerase and the ligand as well as the per-cluster
statistics.
RESULTS
Inhibition of TBEV growth, TBEV-inducedCPE, and viral anti-
gen expression. Six nucleoside analogues with chemical modifi-
FIG 1 The structures of the nucleoside analogues tested in this study. (A) Ribavirin; (B) 6-azauridine; (C) mericitabine; (D) 2=-CMA; (E) 7-deaza-2=-CMA; (F)
2=-CMC.
Nucleoside Inhibitors of TBEV
September 2015 Volume 59 Number 9 aac.asm.org 5485Antimicrobial Agents and Chemotherapy
 o
n
 August 15, 2015 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
cations of the ribose or purine/pyrimidine moiety (Fig. 1) were
tested for the ability to inhibit the growth of the Hypr and Neu-
doerfl TBEV strains in vitro in PS cells and human neuroblastoma
cells. The compounds were tested at a concentration of 50 M,
and the inhibition of TBEV growth was investigated in the culture
supernatants 3 days p.i. using a plaque assay.
The Hypr and Neudoerfl TBEV strains (MOI of 0.1) reached
mean peak titers of 107 and 106 PFU/ml, respectively, in PS cells at
3 days p.i. In human neuroblastoma cells, both TBEV strains
reached a viral titer of approximately 108 PFU/ml at 3 days p.i.
Three of the nucleoside analogues tested, 7-deaza-2=-CMA, 2=-
CMA, and 2=-CMC, inhibited the growth of both TBEV strains in
PS cells and in human neuroblastoma cells. In PS cells, treatment
with 50 M each compound reduced virus titers 104- to 107-fold
compared to that in a mock-treated culture (Fig. 2A and B). Even
greater viral titer reduction (106- to 108-fold) was observed in
TBEV-infected human neuroblastoma cells (Fig. 2C and D).
Ribavirin and mericitabine showed weak or no anti-TBEV ef-
fects in PS cells and human neuroblastoma cells. 6-Azauridine
showed no antiviral effect in PS cells; however, this compound
significantly reduced the viral titer (103-fold for Hypr and 106-fold
for Neudoerfl) in human neuroblastoma cells (Fig. 2B and D).
To verify the primary screening results, we next investigated
the compounds using the CPE inhibition assay. Inhibition of
TBEV-induced CPE in PS cells in the presence of the test com-
pounds was monitored using light microscopy 3 to 4 days p.i. The
TBEV Hypr strain had a strong CPE on the target PS cells on day 3
p.i. in the absence of nucleoside inhibitors (Fig. 3A). A strong CPE
was also observed in PS cell cultures treated with ribavirin (Fig.
3A), mericitabine, and 6-azauridine (see Fig. S1B and C in the
supplemental material), indicating that these compounds had no
protective effects on the survival and growth of PS cells exposed to
TBEV. 6-Azauridine was highly cytotoxic, causing cell death and
morphological changes in PS cells. Both adenosine derivatives,
i.e., 7-deaza-2=-CMA and 2=-CMA, completely inhibited the CPE
at concentrations of 50 M and had no adverse morphological
effects on growing cells. However, a relatively strong CPE was
observed in 2=-CMC-treated PS cell monolayers (Fig. 3A).
The CPE of 7-deaza-2=-CMA, 2=-CMA, and 2=-CMC on
TBEV-infected PS cells was evaluated quantitatively in terms of
cell viability and death using two independent colorimetric in
vitro assays. Mock-treated TBEV-infected PS cells showed a high
rate of cell death, i.e., 46% dead cells, at day 4 p.i. (Fig. 3B; see Fig.
S2 in the supplemental material). TBEV-infected PS cells treated
with either 7-deaza-2=-CMA or 2=-CMA showed a low rate of cell
death (11 to 15%) and high viability (95 to 105%). The measured
values were close to the cell death and viability values determined
for mock-treated uninfected PS cells (11% and 100%, respec-
tively) that were used as negative controls (Fig. 3B; see also Fig. S2
in the supplemental material). The results strongly indicate that
FIG 2 Reduction of TBEV titers by the indicated nucleoside analogues. PS or UKF-NB-4 cells were infected with TBEV (Hypr or Neudoerfl strain) at a
multiplicity of infection of 0.1 and treated with nucleoside analogues at 50 M. The TBEV titers were determined by the plaque assay 3 days postinfection.
DMSO-treated cells were used as a negative control. Bars show the mean values from three biological replicate wells, and the error bars indicate the standard
errors of the means (n 3). ND, not detected (below the detection limit). Horizontal dashed lines indicate the minimum detectable threshold of 1.44 log10 PFU
ml1.
Eyer et al.
5486 aac.asm.org September 2015 Volume 59 Number 9Antimicrobial Agents and Chemotherapy
 o
n
 August 15, 2015 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
7-deaza-2=-CMA and 2=-CMA at concentrations of 50 M com-
pletely protected PS cells from TBEV, allowing them to survive in
the presence of TBEV with no apparent cytotoxicity. For 2=-CMC,
development of the CPE was marked by increased cell death (26
to 28%) and decreased cell viability (54 to 60%) (Fig. 3B; see
also Fig. S2).
The antiviral effect of 7-deaza-2=-CMA, 2=-CMA and 2=-CMC
was further confirmed by immunofluorescence staining, which
was used to assess the expression of the TBEV surface E antigen in
PS cells as an index of viral infectivity and replication in vitro. The
TBEV surface E antigen was strongly expressed in TBEV-infected
mock-treated cells (Fig. 4), and no virus antigen was detected in
mock-infected PS cells (data not shown). Immunofluorescence
staining revealed that 7-deaza-2=-CMA, 2=-CMA, and 2=-CMC at
concentrations of 50 M completely inhibited the expression of
the TBEV surface E antigen in virus-infected PS cells (Fig. 4).
These results correlated with the strong suppression of TBEV
growth in the 7-deaza-2=-CMA-, 2=-CMA-, and 2=-CMC-treated
cell cultures (Fig. 2A and C).
Cytotoxicities of TBEV inhibitors. The cytotoxicities of
7-deaza-2=-CMA, 2=-CMA, and 2=-CMC were evaluated in PS
cells using a cell viability assay (Fig. 5) and subsequently con-
firmed by a cell death assay (see Fig. S3 in the supplemental ma-
terial). No cellular toxicity was seen in cultures of PS cells treated
with 7-deaza-2=-CMA at concentrations ranging from 0 to 50M
(CC50 50 M) 4 days posttreatment (Fig. 5C and Table 1; see
also Fig. S3C). A cell viability assay showed similar results with
2=-CMA (CC50 50 M). However, 50 M 2=-CMA moderately
increased cell death, by22%, at 4 days after drug administration
(Fig. 5A and Table 1; see also Fig. S3A) compared to the rate for
mock-treated cells (15%). For both adenosine derivatives, the
concentration of 50 M had no detectable effect on cell prolifer-
ation. 2=-CMC showed a dose-dependent cytotoxic effect on PS
cell cultures 4 days posttreatment. Based on a cell viability assay,
the CC50 of 2=-CMC was determined to be50 M (Fig. 5B and
Table 1; see also Fig. S3B).
Dose-response antiviral activities of the TBEV inhibitors.
The compounds that showed TBEV inhibitory effects in the initial
experiments, i.e., 7-deaza-2=-CMA, 2=-CMA, and 2=-CMC, were
further evaluated to determine their dose-dependent antiviral ac-
tivities. PS cells were infected with the Hypr strain (MOI of 0.1)
and immediately treated with each compound at a concentration
range of 0 to 50M. The culture supernatants were then subjected
to the plaque assay. TBEV titers in the culture supernatants were
assayed daily on days 1 to 6 p.i. The dose-response curves on
postinfection days 3 and 4 were used to estimate the EC50, SI, and
slope value.
All three compounds reduced the viral titer in a dose-depen-
dent manner (Fig. 6; see also Fig. S4 in the supplemental material).
The shape of the dose-response curves for 7-deaza-2=-CMA
changed over time from a flat curve on day 1 p.i. to typical sigmoi-
dal curves with relatively steep slopes on days 2 to 6 p.i. (Fig. 6A).
FIG 3 Inhibition of the TBEV-induced cytopathic effect by the indicated nucleoside analogues. PS cells were infected with TBEV strain Hypr at a multiplicity of
infection of 0.1 and were left untreated (DMSO) or treated with 50 M ribavirin, 7-deaza-2=-CMA, 2=-CMA, or 2=-CMC. Inhibition of the CPE was monitored
on day 3 or 4 postinfection (A). (B) Quantification of the CPE in TBEV-infected and mock-infected cells treated with 50 M 2=-CMA, 2=-CMC, or 7-deaza-2=-
CMC. The CPE was expressed as the percentage of cell viability at day 4 postinfection. The horizontal dashed line indicates cell viability and cell death in
DMSO-treated uninfected cells (control). The bars indicate the means, and error bars indicate SEMs (n 3).
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7-Deaza-2=-CMA reduced the viral titer, showing an EC50 of 5.1	
0.4M and a selectivity index (SI) of9.8 (Table 1). 7-Deaza-2=-
CMA was ineffective in terms of reducing the viral titer at concen-
trations of 0.1 and 0.5 M, and the TBEV growth curves were
indistinguishable from the TBEV growth curve for mock-treated
cells (see Fig. S4A). At a concentration of 3.1 M, the TBEV in-
hibitory effect of 7-deaza-2=-CMA became more evident, result-
ing in 102-fold reduction in the titer relative to that in mock-
treated cells. Marked inhibitory effects on TBEV replication were
observed at concentrations of 7-deaza-2=-CMA at or above 6.2
M. When the compound was added at concentrations of 12.5,
25, and 50M, there was a significant and steady reduction in viral
titer (a 106- to 107-fold reduction). At these concentrations,
7-deaza-2=-CMA reduced the mean TBEV titers to below the limit
of detection (1.44 log10 PFU ml
1) between p.i. days 4 and 6.
A cytidine derivative, 2=-CMC, also showed marked dose-de-
pendent inhibition of TBEV titers. The shape and particularly the
slope of the 2=-CMC dose-response curve were similar to those of
7-deaza-2=-CMA (Fig. 6B). However, 2=-CMC was approximately
3-fold less potent in terms of inhibiting TBEV than was 7-deaza-
2=-CMA (EC50 of 14.2	 1.9 M) (Table 1). The relatively low SI
value of3.5 was due to the considerable cytotoxicity of the com-
pound for PS cells, as described above. At 0.1, 0.5, and 3.1 M,
2=-CMC inhibited virus replication weakly or not at all. The in-
hibitory effects of 2=-CMC became more evident at concentra-
tions of 6.2 to 12.5M, with virus titer reduction of about 102 at 6
days p.i. 2=-CMC completely suppressed TBEV replication at con-
centrations of 25 and 50 M; there was a 104- to 106-fold reduc-
tion in viral titer during the experimental period (see Fig. S4B in
the supplemental material).
2=-CMA showed a significant dose-dependent antiviral effect
only at day 3 p.i. (Fig. 6C). The 2=-CMA dose-response curve was
characterized by an EC50 of 7.1	 1.2 M (SI of about 7) and by a
relatively low Hill coefficient (0.7 for 2=-CMA versus 2.7 for
7-deaza-2=-CMA and 2.2 for 2=-CMC [Table 1]). At day 3 p.i.,
2=-CMA strongly reduced TBEV titers at concentrations of 20 and
50M, resulting in105-fold viral titer inhibition relative to that
in mock-treated TBEV-infected cells. Although the initial de-
crease in viral titers was very strong, the inhibitory effects of 2=-
CMA diminished gradually after day 3 p.i., regardless of concen-
tration. The decrease in the antiviral effect of 2=-CMA over time
allowed the virus titers in 50M 2=-CMA-treated cells to rebound
to 1.7 106 PFU/ml at day 6 p.i. (see Fig. S4C).
Exploration of NS5Bwith nucleoside analogues using PELE.
Selection and characterization of drug-resistant HCV replicons
revealed that serine 282 (Ser282) determines the efficacy of the
inhibitory nucleoside 2=-CMA (13). Figure S5 in the supplemental
material illustrates the proof of principle for our PELE-based ex-
FIG 4 Inhibition of TBEV viral antigen expression by the indicated nucleoside inhibitors. PS cells were infected with TBEV and treated with 0.5% DMSO or with
50M 7-deaza-2=-CMA, 2=-CMA, or 2=-CMC. PS cells were fixed on slides at day 4 postinfection and stained with flavivirus-specific antibody labeled with FITC
(green) and then counterstained with DAPI (blue). Scale bars, 50 m.
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ploration of nucleoside triphosphate analogues with viral poly-
merases. In the bound crystal structure of HCV (PDB code 1nb6),
the distance between the alpha carbon of Ser282 and the geometric
center of the heavy atoms of UTP is 9.3 Å as measured using the
Maestro package (39). Figure S5 shows that for the most part, UTP
explores20 to 70 Å away from the Ser282 in both the bound and
unbound (or apoenzyme) crystal structures of the HCV polymer-
ase. In both cases, however, there was UTP exploration 
20 Å
away from the Ser282 (encircled in Fig. S5), and this separate
cluster approaches the native position of the bound HCV-UTP
complex (y axes in Fig. S5; i.e., the geometric center position of all
heavy atoms of UTP in PDB code 1nb6).
To further validate the results of the nucleoside triphosphate
analogue exploration, we simulated the experimental results re-
ported by Migliaccio et al. (13), who investigated the inhibitory
effect of 2=-CMA using HCV and other phylogenetically related
viruses in vitro. Figure S6A in the supplemental material shows the
exploration of 2=-CMA-triphosphate (2=-CMA-TP) in proximity
to the homologous serine residue of the viral polymerases of the
HCV (PDB code 1nb6), WNV (PDB code 2hfz), and JEV (PDB
code 4k6m) crystal structures. This analysis showed that 2=-
CMA-TP spent the majority of the exploration away from the
homologous serine residue. Further investigation of whether 2=-
CMA is an effective inhibitor of JEV is needed since no such ex-
periments have been reported. Figure S6B shows that the three
effective nucleoside triphosphate analogues used in the current
study, i.e., 2=-CMA-TP, 2=-CMC-TP, and 7-deaza-2=-CMA-TP,
also explored in proximity to the Ser331 of the modeled tertiary
structure of TBEV NS5B (the residue homologous to HCV
Ser282).
The results from the clustering analysis are summarized in Ta-
ble S1 in the supplemental material. Visual inspection of all three
nucleoside triphosphate analogue clusters for the TBEV polymer-
ase showed two types of clusters. The first type was generated by a
partition of the space sampled in the exploration of each nucleo-
side. Since this zone was densely populated, it was difficult to find
a good balance between cluster compactness and separation
(which would penalize the silhouette index). The second type of
cluster had better-defined boundaries since these clusters formed
“natural” aggregates that were created as the nucleoside explored
the protein surface in proximity to Ser331 of the TBEV polymer-
ase. From this second group or second type of cluster, we selected
those that were 
18 Å from the alpha carbon of Ser331 (green
areas in Fig. 7A). The logic behind this cutoff criterion is depicted
graphically in Fig. S5 in the supplemental material, i.e., the encir-
cled cluster. During the exploration of the HCV polymerase, UTP
approaches the binding site (y axes in Fig. S5; 2 to 12 Å from its
native position) as it “cuts off” from the majority of the modeling
for exploration (18 to 20 Å from Ser282; x axes in Fig. S5).
All three simulations showed a large cluster (colored the same
shade of green in Fig. 7B) with more than half of its elements in
proximity to Ser 331 (especially for 7-deaza-2=-CMA-TP). For
2=-CMA-TP and 2=-CMC-TP, there were elements of other clus-
ters (colored different shades of green in Fig. 7B) that also seemed
to be in proximity to Ser331 of the TBEV polymerase. Assuming
that phylogenetically related viral polymerases have similar bind-
ing sites, we used the central position of UTP bound to HCV (PDB
code 1nb6) to geometrically determine the pathway toward the
predicted binding site of TBEV. The scatter plots in Fig. 7C show
that the majority of modeling for the exploration is away from
Ser331 (i.e., the first type of cluster; 20 Å). Each scatter plot,
however, has a linear correlation (r2) of 0.9, approaching the
predicted binding site of the TBEV polymerase, which is clearly
shown by the large single cluster of 7-deaza-2=-CMA-TP (Fig. 7).
FIG 5 Cytotoxicity of the indicated nucleoside inhibitors. Cytotoxicity was
determined by incubating PS cells with the indicated concentrations of 2=-
CMA (A), 2=-CMC (B), or 7-deaza-2=-CMA (C) and is expressed in terms of
cell viability and cell death at day 4 postinfection. The bars indicate the mean
values from three replicate wells, and the error bars indicate the SEMs.
TABLE 1 Characteristics of selected TBEV-inhibiting nucleosides
Compound
EC50,
Ma
Hill
coefficienta
CC50, M
a
(viability assay)
SI
(CC50/EC50)
7-deaza-2=-CMA 5.1	 0.4 2.7	 0.5 50 9.8
2=-CMA 7.1	 1.2 0.7	 0.1 50 7.0
2=-CMC 14.2	 1.9 2.2	 0.5 50 3.5
a Determined from three independent experiments.
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DISCUSSION
TBE is a substantial public health problem in some parts of Europe
and Asia. At present, there is no specific treatment for TBE other
than supportive care. Few studies have tested potential TBEV in-
hibitors (48), and there is an urgent need for safe, efficient drugs
for treating patients with TBE. In this study, a series of nucleoside
analogues that were previously reported to inhibit members of the
Flaviviridae family were tested for the ability to suppress TBEV
replication. We could not determine the structure-activity rela-
tionship for all of the compounds in this study, although this will
be the subject of a future investigation.
The anti-TBEV activity of the compounds was determined in
PS cells and in human neuroblastoma cells. PS cells are widely
used for TBEV isolation and for multiplication and plaque assays
(30). Human neuroblastoma cells are highly sensitive to TBEV
infection and represent a valuable model for neuropathogenesis
studies of TBEV as well as for studies of several other neurotropic
viruses (31). The initial screening was performed using two TBEV
strains, Neudoerfl and Hypr, which represent two virulence
models. Neudoerfl, the European prototype TBEV strain, ex-
hibits medium virulence, while the Hypr strain is highly viru-
lent (49). Although ribavirin, 6-azauridine, and mericitabine
have been described as potent inhibitors of several flaviviruses
(29, 41, 50), these compounds did not reproducibly inhibit
TBEV in vitro at concentrations of 50 M. 6-Azauridine has
been reported in the literature to be relatively well tolerated by
several host cell lines as well as being well tolerated in vivo (29).
However, in our experiments, this compound had a strong
cytotoxic effect on both PS cells (see Fig. S1C in the supplemen-
tal material) and human neuroblastoma cells (data not shown),
resulting in significantly reduced viral titers in 6-azauridine-
treated human neuroblasts (Fig. 2B and D).
Three 2=-C-methyl-substituted nucleosides, 2=-CMC, 2=-CMA,
and 7-deaza-2=-CMA, strongly inhibited the in vitro growth of
TBEV in both cell lines and were selected as lead candidate com-
pounds for further testing. 2=-CMC was recently tested for its
ability to inhibit replication of yellow fever virus (23), Alkhurma
hemorrhagic fever virus, Kyasanur Forest disease virus, and Omsk
hemorrhagic fever virus (29). Moreover, the 3=-valyl ester of 2=-
CMC, valopicitabine, showed viral load reductions in patients in-
fected with genotype 1 HCV in clinical trials, although it was sub-
sequently discontinued for the treatment of hepatitis C (55, 56).
Our results indicate that 2=-CMC had strong antiviral activity
against both the Hypr and Neudoerfl TBEV strains; however, this
FIG 6 Dose-dependent effect of the indicated TBEV inhibitors on virus titers. PS cells were infected with TBEV at a multiplicity of infection of 0.1 and treated
with 7-deaza-2=-CMA (A), 2=-CMC (B), or 2=-CMA (C) at the indicated concentrations. TBEV titers were monitored at days 1 to 6 postinfection. The mean titers
from three biological replicates are shown, and error bars indicate SEMs (n 3). The horizontal dashed line indicates the minimum detectable threshold of 1.44
log10 PFU ml
1.
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compound was cytotoxic for PS cells (CC50 of about 50 M). The
substitution of cytosine for adenine in 2=-CMA, a compound that
has recently been used for experimental therapy of HCV and
DENV infections (18, 51), significantly reduced the cytotoxicity
for both cell lines and increased the anti-TBEV inhibitory effect of
the compound. However, viral replication gradually rebounded
after 3 days in the treated cultures (Fig. 6C). The observed decrease
in antiviral activity of 2=-CMA and the rebound in viral titer were
probably related to the rapid deamination of 2=-CMA by cellular
adenosine deaminase to the inactive inosine derivative (52). Such
an intracellular deamination is described as an undesirable effect
in the inhibitory activity of 2=-CMA against HCV replication, re-
sulting in poor bioavailability and rapid clearance of 2=-CMA in
plasma (14). 2=-CMA could be also inactivated by cellular phos-
phorylases, which are enzymes that catalyze phosphorolysis of the
purine glycosidic bond (12). Alternatively, the evolution of 2=-
CMA-resistant TBEV mutants could explain the observed viral
titer rebound (53).
The incorporation of the 7-deaza moiety into the 2=-CMA
molecule eliminated cytotoxicity in both PS cells and human neu-
roblastoma cells. The potency of 7-deaza-2=-CMA to inhibit
TBEV replication was comparable to that of 2=-CMA and was
approximately 3-fold higher than that of 2=-CMC. The inhibitory
effect of 7-deaza-2=-CMA was stable over the 6-day experimental
period, and there was no rebound in viral titer during this period.
The 7-deaza-purine substitution is described as an important
modification of the nucleobase that strongly affects the biological
properties of the nucleoside analogue. The 7-deaza modification
alters the glycosyl torsion angle, which may change the glycosyl
bond length. This could lead to a rearrangement in the general
electronic character of the purine base and, in particular, to dis-
ruption of the alignment of the 3=-hydroxyl function for nucleo-
philic attack on the alpha phosphorus of the next incoming NTP.
The 7-deaza modification may, therefore, result in enhanced po-
tency of the nucleoside analogue in terms of terminating viral
RNA synthesis (9, 14). Due to the antiviral activity and low cyto-
toxicity of 7-deaza-2=-CMA, this nucleoside derivative has been
widely tested to determine whether it inhibits the RNA replication
of other medically important flaviviruses. For example, 7-deaza-
2=-CMA inhibits HCV replication with an EC50 of 0.3M with no
apparent cytotoxicity and shows promising pharmacokinetic
properties in several animal species, including primates (14,
54). Similar antiviral properties have been demonstrated for
the 7-deaza-substituted derivative of 2=-C-acetylene-adeno-
FIG 7 Cluster analyses of nucleoside triphosphate analogue exploration of the TBEV polymerase. (A) The distance for each of the studied nucleoside triphos-
phate analogues (2=-CMA-TP, 2=-CMC-TP, and 7-deaza-2=-CMA-TP) are shown in the histograms. The 0- to 18-Å range, which denotes the proximity toward
Ser331 (x axes), is colored light green. (B) Tertiary representations of the selected clusters for each system. Each nucleoside is represented by its C-7 atom. (C)
Scatter plots depict the approach of each nucleoside toward the predicted binding site of TBEV.
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sine, which was recently reported to suppress DENV replica-
tion in the transient-replicon assay and in a mouse model (18).
To understand the efficacies of 2=-CMA, 2=-CMC, and
7-deaza-2=-CMA for inhibiting TBEV, we simulated the explora-
tion of the TBEV polymerase by the triphosphate form of each
nucleoside analogue (Fig. 7). The computational simulations
showed that these inhibitors sampled toward the binding site of
the TBEV polymerase. There are a couple of other clusters that
aggregate toward the TBEV binding site for 2=-CMA-TP and 2=-
CMC-TP. Based on our experimental results, we infer that the
pathway is represented by the single cluster of 7-deaza-2=-
CMA-TP in Fig. 7, but a more robust analysis must be performed
to confirm this hypothesis. Takhampunya et al. (41) developed a
method for calculating the ligand/drug binding free energy during
its exploration toward the active site of a protein. Their results
showed strong correlations with experimental data. We are cur-
rently using such methods to determine the viral polymerase
binding pathways of 2=-CMA, 2=-CMC, and 7-deaza-2=-CMA and
their binding free energies.
In conclusion, we identified three compounds with activity
against TBEV in vitro. These compounds will be tested further in a
mouse model of TBEV infection. These compounds, even if they
are not clinically effective, may be useful research tools or starting
points for drug development efforts against TBEV. Because of its
high antiviral activity and low cytotoxicity, 7-deaza-2=-CMA is an
attractive candidate for further investigation as a potential thera-
peutic agent not only for TBE treatment but also for treating other
flaviviral neuroinfections.
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